Dr. Jill's Women's I Group

The 2026 transposition of the NIS 2 Directive into German law has forced a massive upgrade in the cybersecurity of marketing databases. Pharmaceutical companies are now classified as "Important Entities,"

meaning their marketing data repositories must meet the same security standards as their manufacturing plants. This has led to the widespread adoption of Blockchain-based Consent Management, where a patient’s "Right to be Forgotten" or their opt-in preferences are recorded on a tamper-proof ledger. For German advertisers, this is not just a compliance task but a marketing advantage, as it proves to a skeptical German public that their sensitive health data is being handled with "Bank-Grade" security.